TransCode Therapeutics (NASDAQ:RNAZ) Now Covered by HC Wainwright

Stock analysts at HC Wainwright assumed coverage on shares of TransCode Therapeutics (NASDAQ:RNAZGet Rating) in a research report issued on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.

Shares of NASDAQ RNAZ opened at $1.76 on Tuesday. The company has a market cap of $22.84 million and a P/E ratio of -9.26. TransCode Therapeutics has a 1 year low of $1.52 and a 1 year high of $7.00. The firm has a 50-day simple moving average of $2.49 and a two-hundred day simple moving average of $2.46.

TransCode Therapeutics (NASDAQ:RNAZGet Rating) last posted its quarterly earnings results on Thursday, March 31st. The company reported ($0.23) earnings per share for the quarter.

Institutional investors have recently bought and sold shares of the company. K.J. Harrison & Partners Inc bought a new stake in shares of TransCode Therapeutics during the fourth quarter valued at approximately $41,000. Geode Capital Management LLC bought a new stake in shares of TransCode Therapeutics during the third quarter valued at approximately $50,000. National Asset Management Inc. bought a new stake in shares of TransCode Therapeutics during the third quarter valued at approximately $75,000. Two Sigma Securities LLC bought a new stake in shares of TransCode Therapeutics during the third quarter valued at approximately $100,000. Finally, ACT Capital L.L.C. bought a new stake in shares of TransCode Therapeutics during the third quarter valued at approximately $150,000. 18.23% of the stock is owned by hedge funds and other institutional investors.

TransCode Therapeutics Company Profile (Get Rating)

TransCode Therapeutics, Inc, a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.

See Also

The Fly logo

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.